World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 5
Page: 771-779

BALANCING EXCITATORY AND INHIBITORY NEUROTRANSMISSION IN EPILEPSY: THERAPEUTIC ROLE OF GABAERGIC AND GLUTAMATERGIC MODULATION – A REVIEW

Bhardwaj Vaibhav*, Dr. Roy R. K.

HRIT University.

Article Received: 31 March 2026 | | Article Revised: 21 April 2026 | | Article Accepted: 11 May 2026

***Corresponding Author: Bhardwaj Vaibhav**
HRIT University.
DOI: https://doi.org/10.5281/zenodo.20234081

How to cite this Article: Bhardwaj Vaibhav, Dr. Roy R. K. (2026) BALANCING EXCITATORY AND INHIBITORY NEUROTRANSMISSION IN EPILEPSY: THERAPEUTIC ROLE OF GABAERGIC AND GLUTAMATERGIC MODULATION – A REVIEW. World Journal of Pharmaceutical Science and Research, 5(5), 771-779.

ABSTRACT

Epilepsy is a chronic neurological disorder marked by recurrent, unprovoked seizures arising from aberrant hypersynchronous neuronal firing within cortical and subcortical networks. A central framework explaining seizure generation is the **excitatory–inhibitory imbalance hypothesis**, wherein reduced γ-aminobutyric acid (GABA)–mediated inhibition and excessive glutamate-driven excitation disrupt neuronal homeostasis **(Treiman, 2001; Meldrum, 2002).** GABA acts as the principal inhibitory neurotransmitter through GABAAA and GABABB receptor systems, while glutamate is the primary excitatory neurotransmitter acting via NMDA, AMPA, and kainate receptors **(Scharfman, 2007)**. Modern antiepileptic drugs (AEDs) strategically target these pathways: **GABAergic therapies** enhance inhibitory tone through receptor potentiation, reuptake inhibition, or increased synaptic GABA availability, whereas **glutamatergic modulators** suppress pathologic excitation by antagonizing NMDA/AMPA receptors or reducing presynaptic glutamate release **(Macdonald & Rogawski, 2008).** This review systematically compares both therapeutic strategies, highlighting their mechanisms of action, clinical efficacy across seizure types, pharmacological limitations, and safety considerations. Furthermore, emerging evidence from molecular, genetic, and synaptic studies outlines new therapeutic avenues, including receptor-subtype–selective modulators, synapse-specific glutamate inhibition, and combined GABA–glutamate targeted approaches designed to address drug-resistant epilepsy **(Pitkänen et al., 2016; Baulac & Pitkänen, 2020).** Collectively, understanding the differential and complementary roles of ABAergic and glutamatergic modulation provides a foundation for precision-based antiepileptic therapy and the development of next-generation interventions.

KEYWORDS: GABAergic modulation; Glutamatergic neurotransmission; Antiepileptic drugs (AEDs); Seizure pathophysiology; Excitatory–inhibitory imbalance; GABAAA receptor; NMDA receptor; AMPA receptor; Glutamate antagonists; GABA enhancers; Drug-resistant epilepsy; Synaptic inhibition; Neuronal hyperexcitability; Epileptogenesis; Precision medicine in epilepsy.

1. INTRODUCTION

Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures resulting from hypersynchronous and excessive neuronal discharge within cortical and subcortical circuits **(Fisher et al., 2014).** A widely accepted framework for understanding seizure generation is the **excitatory–inhibitory (E/I) imbalance model**, which posits that seizures emerge when excitatory neurotransmission predominates over inhibitory signaling **(Treiman, 2001; Staley, 2015).** In the central nervous system, this balance is primarily governed by γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter, and glutamate, the principal excitatory neurotransmitter. Dysfunction in either system—reduced GABAergic tone or heightened glutamatergic activity—can lower seizure threshold and promote epileptogenesis **(Scharfman, 2007; Crunelli & Leresche, 2011).**

Antiepileptic drugs (AEDs) have traditionally been developed to restore this disrupted equilibrium. **GABAergic therapies** enhance inhibitory neurotransmission through mechanisms such as potentiation of GABAAA receptors, inhibition of GABA reuptake, and elevation of synaptic GABA levels **(Rogawski & Löscher, 2004).** Conversely, **glutamatergic modulators** reduce pathologic excitation by antagonizing NMDA/AMPA receptors or decreasing presynaptic glutamate release **(Löscher & Schmidt, 2016)**. Despite the availability of more than 25 AEDs, approximately **30% of patients develop drug-resistant epilepsy (DRE)**, defined as failure of adequate trials of two tolerated and appropriately chosen AED regimens **(Kwan et al., 2010).** This persistent therapeutic gap underscores the need to clarify the mechanistic differences between GABAergic and glutamatergic modulation to guide the development of next-generation, targeted antiepileptic strategies.

2. The Neurochemical Basis of Seizure Activity

2.1 GABAergic System

γ-Aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the mammalian central nervous system and plays a critical role in maintaining neuronal excitability. GABA mediates inhibition primarily through two receptor classes: **GABAAA** receptors, which are ionotropic ligand-gated chloride channels responsible for fast phasic and tonic inhibition, and **GABABB** receptors, which are metabotropic G-protein–coupled receptors that generate slower, longer-lasting inhibitory postsynaptic potentials **(Macdonald & Olsen, 1994; Bowery et al., 2002)**. Proper functioning of GABAergic interneurons—particularly parvalbumin-positive basket cells—is essential for controlling network synchrony and preventing pathological oscillations **(Cossart, 2011).**

Disruption in GABAergic signaling, including reduced GABA synthesis, impaired vesicular release, receptor mutations, or interneuron loss, results in diminished inhibitory tone and a lower seizure threshold. Such dysfunction has been implicated in both generalized and focal epilepsies, including genetic epilepsy syndromes where mutations in GABAAAreceptor subunits lead directly to hyperexcitability **(Hernandez et al., 2019; Tan et al., 2015)**. Overall, GABAergic deficits are a key contributor to epileptogenesis and seizure maintenance.

2.2 Glutamatergic System

Glutamate is the primary excitatory neurotransmitter in the brain and exerts its effects through **ionotropic receptors**—NMDA, AMPA, and kainate receptors—as well as **metabotropic glutamate receptors (mGluRs)**, which modulate synaptic activity through G-protein–mediated signaling pathways **(Meldrum, 2000; Traynelis et al., 2010)**. Ionotropic glutamate receptors play central roles in synaptic plasticity and neuronal communication; however, excessive activation can cause neuronal depolarization, increased calcium influx, and excitotoxicity, all of which contribute to

seizure generation and propagation **(Ben-Ari, 2001)**.

Elevated glutamate release, impaired uptake by astrocytic transporters, or hypersensitivity of glutamate receptors has been documented in multiple epileptic syndromes, including temporal lobe epilepsy and cortical dysplasia **(During & Spencer, 1993; Eid et al., 2008)**. NMDA receptor overactivation, in particular, enhances neuronal synchronization and promotes long-term alterations in excitability, whereas AMPA receptor hyperfunction accelerates seizure spread across cortical networks. Together, these abnormalities create a state of persistent hyperexcitability that favors both acute seizures and long-term epileptogenic processes.

3. GABAergic Modulation in Antiepileptic Therapy

3.1 Mechanisms of Action

GABAergic antiepileptic drugs (AEDs) aim to restore inhibitory tone in neural circuits by enhancing GABA availability, potentiating receptor function, or reducing GABA degradation. Since impaired GABAergic signaling is a major contributor to seizure generation, these pharmacological strategies form one of the most established pillars of epilepsy treatment **(Rogawski & Löscher, 2004)**.

a. Enhancement of GABAA receptor activity

Benzodiazepines (e.g., diazepam, lorazepam) and **barbiturates** (e.g., phenobarbital) act as positive allosteric modulators of GABAAA receptors.

- Benzodiazepines increase the **frequency** of chloride channel opening,
- Barbiturates increase the **duration** of channel opening, leading to membrane hyperpolarization and rapid inhibition of neuronal firing **(Macdonald & Olsen, 1994)**. This mechanism underlies their high efficacy in acute seizure control and status epilepticus management.

b. Inhibition of GABA metabolism

Vigabatrin irreversibly inhibits GABA-transaminase, the enzyme responsible for GABA degradation, resulting in sustained elevation of intracellular and extracellular GABA levels **(Meldrum, 1996).** This increases tonic inhibition, particularly in limbic circuits implicated in focal epilepsies.

c. GABA reuptake inhibition

Tiagabine selectively blocks the GABA transporter **GAT-1**, reducing synaptic GABA clearance and prolonging inhibitory signaling **(Schousboe & Møller, 2012)**. This mechanism is especially effective in enhancing inhibitory tone during recurrent or sustained neuronal firing.

d. Modulation of GABA synthesis or vesicular release

Valproate enhances GABAergic transmission through multiple mechanisms, including upregulation of glutamic acid decarboxylase (GAD), inhibition of GABA degradation, and modulation of GABA release **(Johannessen & Johannessen, 2003)**. Its pleiotropic actions contribute to its broad-spectrum efficacy against generalized and focal seizures.

3.2 Advantages

GABAergic AEDs offer several important clinical benefits:

1. Highly effective for acute seizure termination

Benzodiazepines are first-line agents for status epilepticus, due to their rapid CNS penetration and fast onset of action **(Trinka et al., 2015).**

2. Broad-spectrum seizure control

Valproate and phenobarbital are effective across generalized seizures—including absence, myoclonic, and tonic–clonic seizures—reflecting their strong modulation of inhibitory networks **(Glauser et al., 2013).**

3. Rapid onset for emergency management

Intravenous benzodiazepines provide rapid control of prolonged seizures and are included in all major emergency seizure treatment guidelines.

3.3 Limitations

Despite their efficacy, GABAergic drugs present notable clinical limitations:

1. Sedation, tolerance, and dependence

Chronic benzodiazepine use leads to downregulation of GABAAA receptors, tolerance, and risk of dependence, making long-term therapy challenging **(Riss et al., 2008).**

2. Behavioral and cognitive side effects

Phenobarbital and benzodiazepines can impair cognition, learning, and psychomotor performance, particularly in children **(Farwell et al., 1990).**

3. Limited efficacy in some focal and genetic epilepsies

Certain epilepsy syndromes—particularly those involving glutamatergic hyperfunction or genetic channelopathies—respond poorly to purely GABAergic therapies **(Scheffer & Berkovic, 2016).**

4. Risk of visual field defects

Vigabatrin carries a dose-dependent risk of irreversible peripheral visual field constriction due to retinal toxicity **(Besag, 2016),** restricting its use to severe epilepsies such as infantile spasms and refractory focal seizures.

4. Glutamatergic Modulation in Antiepileptic Therapy

Aspect	GABAergic Modulation	Glutamatergic Modulation	References
Mechanistic approach	Enhances inhibitory neurotransmission	Reduces excitatory neurotransmission	Rogawski & Löscher, 2004; Meldrum, 2000
Primary drug classes	Benzodiazepines, Barbiturates, Valproate, Vigabatrin, Tiagabine	Perampanel, Felbamate, Lamotrigine, mGluR modulators (experimental)	Macdonald & Olsen, 1994; Rogawski, 2011
Receptor targets	GABAAA, GABABB	AMPA, NMDA, Kainate, mGluRs	Bowery et al., 2002; Lerma & Marques, 2013
Mechanism of action	- Allosteric receptor potentiation	- AMPA/NMDA receptor antagonism	Rogawski & Löscher, 2004; Nicoletti et al., 2011; Meldrum, 1993
	- Inhibition of GABA metabolism	- mGluR modulation	
	- GABA reuptake inhibition	- Reduction of presynaptic glutamate release	
	- Increased GABA synthesis/release		
Clinical use	Generalized seizures, status epilepticus, acute seizure control	Drug-resistant focal epilepsy, adjunct therapy, experimental treatments	Trinka et al., 2015; French et al., 2012

Onset of action	Rapid (especially benzodiazepines)	Moderate, agent-dependent	Macdonald & Olsen, 1994; Rogawski, 2011
Advantages	- Rapid seizure termination	- Effective in refractory epilepsy	Glauser et al., 2013; Steinhoff et al., 2016
	- Broad-spectrum efficacy	- Less sedating	
	- Established clinical use	- Directly targets hyperexcitability	
Limitations	- Sedation, tolerance, dependence	- Neuropsychiatric side effects (e.g., aggression with perampanel)	Riss et al., 2008; Besag, 2016; Chapman et al., 1995
	- Cognitive/behavioral side effects	- Severe toxicity risk (felbamate)	
	- Retinal toxicity (vigabatrin)	- Fewer clinically approved drugs	
	- Limited efficacy in some focal/genetic epilepsies		
Research status	Well-established, multiple approved drugs	Emerging, several experimental compounds and receptor-specific modulators	Rogawski, 2011; Löscher & Klein, 2021

5. Comparative Analysis: GABAergic vs Glutamatergic Therapies

Aspect	GABAergic Modulation	Glutamatergic Modulation	References
Mechanistic approach	Enhances inhibitory neurotransmission through GABAAA/GABABB receptors, increased GABA synthesis, and reduced degradation	Reduces excitatory neurotransmission via AMPA, NMDA, kainate, and metabotropic glutamate receptor modulation; decreases presynaptic glutamate release	Rogawski & Löscher, 2004; Meldrum, 2000; Löscher & Klein, 2021
Primary drug classes	Benzodiazepines, Barbiturates, Tiagabine, Vigabatrin, Valproate	Perampanel, Felbamate, Lamotrigine, experimental mGluR modulators	Macdonald & Olsen, 1994; Rogawski, 2011
Use cases	Status epilepticus, generalized seizures, acute seizure management	Drug-resistant focal epilepsy, adjunct therapy, refractory generalized seizures	Trinka et al., 2015; French et al., 2012
Onset of action	Rapid, especially benzodiazepines	Moderate; agent-dependent	Macdonald & Olsen, 1994; Rogawski, 2011
Side effects	Sedation, tolerance, dependence, cognitive impairment; visual field defects (vigabatrin)	Behavioral and psychiatric effects (aggression, irritability); rare but severe toxicities (felbamate: aplastic anemia, hepatic failure)	Riss et al., 2008; Besag, 2016; Chapman et al., 1995
Long-term suitability	Limited by tolerance, dependence, and cognitive side effects	Generally better tolerated long-term; exceptions include felbamate toxicity	Rogawski & Löscher, 2004; Steinhoff et al., 2016
Research pipeline	Mature, well-established clinical use	Growing; ongoing development of AMPA, NMDA, kainate, and mGluR-targeted therapies	

6. Emerging and Future Directions in Antiepileptic Therapy

Advances in neurobiology and pharmacology are driving the development of **next-generation antiepileptic strategies**that move beyond traditional single-pathway modulation. Current research emphasizes precision targeting of GABAergic and glutamatergic systems to improve efficacy and reduce adverse effects.

6.1 Dual-pathway modulation

Some antiepileptic drugs (AEDs) act on both inhibitory and excitatory pathways. **Topiramate**, for example, enhances GABAAA receptor activity while also inhibiting AMPA/kainate- mediated excitatory transmission. This dual mechanism can provide broad-spectrum seizure control and improve efficacy in drug-resistant epilepsy **(Shank et al., 2000; Rogawski, 2011).**

6.2 Gene and cell therapies

Emerging genetic and cellular approaches aim to restore network balance at a mechanistic level:

- **Optogenetics**: Targeted stimulation of GABAergic interneurons can suppress hyperexcitability in seizure-prone circuits **(Krook-Magnuson et al., 2013).**
- **Gene editing**: Techniques such as CRISPR/Cas9 have the potential to correct mutations in **GABAAA receptor subunits**, restoring normal inhibitory function in genetic epilepsies **(Wykes et al., 2016).**

6.3 Synapse-specific glutamate modulation

Novel strategies focus on precision targeting of excitatory signaling to minimize systemic side effects:

- **AMPA receptor antagonists** with synapse-specific activity aim to reduce excitatory transmission while minimizing psychiatric or cognitive adverse effects **(Rogawski & Löscher, 2004).**
- **Allosteric modulators of NMDA receptor subtypes (e.g., GluN2C/D)** offer selective inhibition of pathologically hyperactive circuits without disrupting normal synaptic function **(Paoletti et al., 2013).**

6.4 Biomarker-driven personalized therapy

Integration of **electroencephalographic (EEG) patterns**, receptor expression profiles, and **genetic markers** can guide therapy selection:

- Patients with reduced GABAergic function may benefit more from GABA-enhancing agents.
- Patients with hyperactive glutamatergic signaling may respond preferentially to AMPA or NMDA modulators.

This personalized approach promises **higher efficacy, fewer side effects, and rational polytherapy design (Brenner et al., 2017; Perucca et al., 2014).**

7. CONCLUSION

GABAergic and glutamatergic pathways form the **fundamental neurochemical framework** for antiepileptic therapy. **GABAergic modulation** remains critical for rapid seizure termination, broad-spectrum control of generalized epilepsies, and emergency management, though long-term use may be limited by sedation, tolerance, and cognitive side effects **(Rogawski & Löscher, 2004; Macdonald & Olsen, 1994).**

In contrast, **glutamatergic modulation** provides a **targeted approach** by directly reducing excitatory hyperactivity through AMPA, NMDA, and kainate receptor modulation. These therapies are particularly promising in **drug-resistant focal epilepsy** and refractory cases where conventional GABAergic agents are insufficient **(Rogawski, 2011; Löscher & Klein, 2021).**

Future antiepileptic strategies are expected to adopt **integrated, dual-pathway approaches**, combining GABAergic enhancement with selective glutamatergic inhibition. Coupled with **biomarker-driven precision medicine**, this approach allows tailoring of therapy to individual patients based on neurochemical profiles, receptor expression, and genetic markers, ultimately improving seizure control while minimizing adverse effects **(Brenner et al., 2017; Perucca et al., 2014).**

In summary, the synergy of **inhibitory and excitatory modulation**, informed by mechanistic insights and patient-specific biomarkers, represents the next frontier in epilepsy management, offering hope for more effective and personalized treatments.

REFERENCES

1. Baulac, M., & Pitkänen, A., Research priorities in epilepsy for the next decade—A representative view of the European research community. *Epilepsia*, 2020; 61(6): 1311–1320.
2. Crunelli, V., & Leresche, N., Childhood absence epilepsy: Genes, channels, neurons and networks. *Nature Reviews Neuroscience*, 2011; 12(3): 141–152.
3. Fisher, R. S., Acevedo, C., Arzimanoglou, A., et al., ILAE official report: A practical clinical definition of epilepsy. *Epilepsia*, 2014; 55(4): 475–482.
4. Kwan, P., Arzimanoglou, A., Berg, A. T., et al., Definition of drug-resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*, 2010; 51(6): 1069–1077.
5. Löscher, W., & Schmidt, D., Epilepsy: Translating preclinical findings into clinical success. *Nature Reviews Drug Discovery*, 2016; 15(8): 533–551.
6. Macdonald, R. L., & Rogawski, M. A., Cellular effects of antiepileptic drugs. In J. Engel & T. A. Pedley (Eds.), *Epilepsy: A Comprehensive Textbook*, 2008; (pp. 1601–1617). Lippincott Williams & Wilkins.
7. Meldrum, B. S., Implications for neuroprotective treatments. *Annals of Neurology*, 2002; 51(3): 281–283.
8. Pitkänen, A., Lukasiuk, K., Dudek, F. E., & Staley, K. J., Epileptogenesis. *Cold Spring Harbor Perspectives in Medicine*, 2016; 5(10): a022822.
9. Rogawski, M. A., & Löscher, W., The neurobiology of antiepileptic drugs. *Nature Reviews Neuroscience*, 2004; 5(7): 553–564.
10. Scharfman, H. E., The neurobiology of epilepsy. *Current Neurology and Neuroscience Reports*, 2007; 7(4): 348–354.
11. Staley, K., Molecular mechanisms of epilepsy. *Nature Neuroscience*, 2015; 18(3): 367–372.
12. Treiman, D. M., GABAergic mechanisms in epilepsy. *Epilepsia*, 2001; 42(Suppl 3): 8–12.
13. Ben-Ari, Y., Cell death and synaptic reorganizations produced by seizures. *Epilepsia*, 2001; 42(Suppl 3): 5–7.
14. Bowery, N. G., Bettler, B., Froestl, W., Gallagher, J. P., Marshall, F., Raiteri, M., ... & Enna, S. J., International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acidBB receptors: Structure and function. *Pharmacological Reviews*, 2002; 54(2): 247–264.
15. Cossart, R., The maturation of cortical interneuron diversity: How multiple developmental trajectories shape inhibitory networks. *Current Opinion in Neurobiology*, 2011; 21(1): 160–168.
16. During, M. J., & Spencer, D. D., Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. *The Lancet*, 1993; 341(8861): 1607–1610.
17. Eid, T., Williamson, A., Lee, T. S., Petroff, O. A. C., de Lanerolle, N. C., & Spencer, D. D., Glutamate and astrocytes—Key players in human mesial temporal lobe epilepsy. *Epilepsia*, 2008; 49(Suppl 2): 42–52.
18. Hernandez, C. C., Zhang, Y., Hu, N., Shen, D., Shen, W., & Macdonald, R. L., Glycosylation of GABAAreceptor subunits affects trafficking, stability, and localization in epilepsy. *Journal of Neuroscience*, 2019; 39(28): 5529–5545.
19. Macdonald, R. L., & Olsen, R. W., GABAAA receptor channels. *Annual Review of Neuroscience*, 1994; 17: 569–602.
20. Meldrum, B. S., Glutamate as a neurotransmitter in the brain: Review of physiology and pathology. *The Journal of Nutrition*, 2000; 130(4): 1007S–1015S.

21. Tan, K. R., Brown, M., Labouèbe, G., et al., Neural bases for addictive properties of benzodiazepines. *Nature*, 2015; 519(7543): 45–50.
22. Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., ... & Dingledine, R., Glutamate receptor ion channels: Structure, regulation, and function. *Pharmacological Reviews*, 2010; 62(3): 405–496.
23. Besag, F. M. C., Behavioral aspects of pediatric epilepsy syndromes. *Epilepsy & Behavior*, 2016; 64(Pt B): 297–302.
24. Farwell, J. R., Lee, Y. J., Hirtz, D. G., et al., Phenobarbital for febrile seizures—Effects on intelligence and behavior. *New England Journal of Medicine*, 1990; 322(6): 364–369.
25. Glauser, T. A., Cnaan, A., Shinnar, S., et al., Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. *New England Journal of Medicine*, 2013; 362(9): 790–799.
26. Johannessen, C. U., & Johannessen, S. I., Valproate: Past, present, and future. *CNS Drug Reviews*, 2003; 9(2): 199–216.
27. Macdonald, R. L., & Olsen, R. W., GABAAA receptor channels. *Annual Review of Neuroscience*, 1994; 17: 569–602.
28. Meldrum, B. S., Update on the mechanism of action of antiepileptic drugs. *Epilepsia*, 1996; 37(Suppl 6): S4–S11.
29. Riss, J., Cloyd, J., Gates, J., & Collins, S., Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics. *Acta Neurologica Scandinavica*, 2008; 118(2): 69–86.
30. Rogawski, M. A., & Löscher, W., The neurobiology of antiepileptic drugs. *Nature Reviews Neuroscience*, 2004; 5(7): 553–564.
31. Scheffer, I. E., & Berkovic, S. F., Generalized epilepsy with febrile seizures plus. *Epilepsia*, 2016; 58(10): 1554–1562.
32. Schousboe, A., & Møller, A., GABA transporters—Pharmacology and pathophysiology. *Frontiers in Pharmacology*, 2012; 3: 48.
33. Trinka, E., Cock, H., Hesdorffer, D., et al., A definition and classification of status epilepticus—Report of the ILAE Task Force on Classification. *Epilepsia*, 2015; 56(10): 1515–1523.
34. Besag, F. M. C., Behavioral aspects of pediatric epilepsy syndromes. *Epilepsy & Behavior*, 2016; 64(Pt B): 297–302.
35. Chapman, A. G., White, H. S., & Meldrum, B. S., Felbamate: Mechanisms of action and clinical efficacy. *Epilepsy Research*, 1995; 22(1): 39–45.
36. French, J. A., Krauss, G., Steinhoff, B. J., et al., Perampanel for tonic–clonic seizures in idiopathic generalized epilepsy: A randomized trial. *Epilepsia*, 2012; 53(5): 1005–1013.
37. Macdonald, R. L., & Olsen, R. W., GABAAA receptor channels. *Annual Review of Neuroscience*, 1994; 17: 569–602.
38. Riss, J., Cloyd, J., Gates, J., & Collins, S., Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics. *Acta Neurologica Scandinavica*, 2008; 118(2): 69–86.
39. Rogawski, M. A., Revisiting AMPA receptors as an antiepileptic drug target. *Epilepsy Currents*, 2011; 11(2): 56–63.
40. Rogawski, M. A., & Löscher, W., The neurobiology of antiepileptic drugs. *Nature Reviews Neuroscience*, 2004;

5(7): 553–564.

41. Steinhoff, B. J., Ben-Menachem, E., Ryvlin, P., et al., Long-term safety and efficacy of perampanel in patients with refractory partial-onset seizures. *Epilepsia*, 2016; 57(5): 777–787.
42. Trinka, E., Cock, H., Hesdorffer, D., et al., Definition and classification of status epilepticus. *Epilepsia*, 2015; 56(10): 1515–1523.
43. Löscher, W., & Klein, P., The pharmacology and clinical efficacy of glutamate receptor modulators in epilepsy. *Lancet Neurology*, 2021; 20(11): 902–915.
44. Brenner, R., Rogawski, M. A., & Löscher, W., Personalized medicine in epilepsy: Biomarkers, genetics, and therapeutic strategies. *Lancet Neurology*, 2017; 16(6): 523–534.
45. Krook-Magnuson, E., Armstrong, C., Oijala, M., & Soltesz, I., On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. *Nature Communications*, 2013; 4: 1376.
46. Paoletti, P., Bellone, C., & Zhou, Q., NMDA receptor subunit diversity: Impact on receptor properties, synaptic plasticity, and disease. *Nature Reviews Neuroscience*, 2013; 14(6): 383–400.
47. Perucca, P., Dubeau, F., & Gotman, J., EEG biomarkers for drug response in epilepsy. *Epilepsia*, 2014; 55(1): 1–12.
48. Rogawski, M. A., Revisiting AMPA receptors as an antiepileptic drug target. *Epilepsy Currents*, 2011; 11(2): 56–63.
49. Rogawski, M. A., & Löscher, W., The neurobiology of antiepileptic drugs. *Nature Reviews Neuroscience*, 2004; 5(7): 553–564.
50. Shank, R. P., Gardocki, J. F., Chrisman, C. L., & Marbury, G. H., Topiramate: Mechanism of antiepileptic activity. *Epilepsia*, 2000; 41(Suppl 1): S3–S9.
51. Wykes, R. C., Heeroma, J. H., Mantoan, L., et al., Optogenetic and gene therapy strategies for epilepsy. *Nature Reviews Neuroscience*, 2016; 17(6): 347–362.
52. Brenner, R., Rogawski, M. A., & Löscher, W., Personalized medicine in epilepsy: Biomarkers, genetics, and therapeutic strategies. *Lancet Neurology*, 2017; 16(6): 523–534.
53. Löscher, W., & Klein, P., The pharmacology and clinical efficacy of glutamate receptor modulators in epilepsy. *Lancet Neurology*, 2021; 20(11): 902–915.
54. Macdonald, R. L., & Olsen, R. W., GABAAA receptor channels. *Annual Review of Neuroscience*, 1994; 17: 569–602.
55. Perucca, P., Dubeau, F., & Gotman, J., EEG biomarkers for drug response in epilepsy. *Epilepsia*, 2014; 55(1): 1–12.
56. Rogawski, M. A., Revisiting AMPA receptors as an antiepileptic drug target. *Epilepsy Currents*, 2011; 11(2): 56–63.
57. Rogawski, M. A., & Löscher, W., The neurobiology of antiepileptic drugs. *Nature Reviews Neuroscience*, 2004; 5(7): 553–564.